Alteogen Inc

Alteogen Inc maintains a strong liquidity position, with a current ratio of 2.01 and free cash flow of 117,245,087,620 KRW, indicating the company's ability to meet short-term obligations and fund operations without external financing. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.23 suggests a conservative capital structure, with long-term debt at 100,798,982,310 KRW and total equity at 445,194,059,010 KRW. The company's profitability is robust, with a return on equity (ROE) of 31.82% and a return on assets (ROA) of 20.27%, both significantly above the industry median for biotechnology firms. Operating income of 137,325,388,120 KRW and net income of 141,666,024,710 KRW reflect strong operational efficiency and cost control. Gross profit of 165,625,058,900 KRW on revenue of 215,858,918,960 KRW indicates a healthy gross margin, supporting the company's competitive positioning in the biosimilars market. Geographically, Alteogen Inc's revenue is concentrated in South Korea, with no disclosed international revenue segments. The company's product portfolio is centered on biosimilars and biologics, with no material diversification across therapeutic areas or customer bases. This concentration increases exposure to domestic regulatory and market risks, particularly in the South Korean healthcare sector. The company's growth trajectory is positive, with revenue of 215,858,918,960 KRW in the latest period. Analysts project a mean price target of 437,500 KRW per share, with a median of 460,000 KRW, suggesting a consensus for continued value creation. The mean recommendation of 2.00 (on a 1-5 scale) indicates a generally positive outlook, with two strong-buy and three buy ratings. However, the absence of hold or sell ratings suggests limited downside risk in the near term. Risk factors include the company's reliance on a narrow product portfolio and geographic exposure, as well as the potential for dilution if the company issues additional shares. The risk assessment indicates a low dilution risk, with no immediate pressure for equity issuance. However, the company's capital expenditure of -33,417,380,510 KRW suggests ongoing investment in R&D or infrastructure, which could impact near-term cash flow. Recent events include the continued expansion of the company's biosimilar pipeline and the strengthening of its market position in South Korea. No recent filings or transcripts indicate material changes in strategy or operations, and the company remains focused on its core therapeutic areas.